RTW Investments SABSW Position
Exited4-Fund ConvergenceRTW Investments exited their position in SAB Biotherapeutics, Inc. (SABSW) in Q4 2024, after holding the stock for 5 quarters.
The position was first reported in Q4 2023 and has been tracked across 5 quarterly 13F filings.
SABSW is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for High Dose SAB-142 in 593 days (Nov 30, 2027), making the timing of RTW Investments's position particularly relevant.
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.
Full company profile →RTW Investments SABSW Position History
Frequently Asked Questions
Does RTW Investments own SABSW?
No. RTW Investments exited their position in SAB Biotherapeutics, Inc. (SABSW) in Q4 2024. They previously held the stock for 5 quarters.
How many hedge funds own SABSW?
4 specialist biotech hedge funds currently hold SABSW, including RA Capital Management, Commodore Capital, BVF Partners and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did RTW Investments first buy SABSW?
RTW Investments's position in SABSW was first reported in Q4 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is RTW Investments's SABSW position increasing or decreasing?
RTW Investments completely exited their SABSW position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
SABSWCompany Page →
All fund holders, insider trades, catalysts, and cash runway
RTW InvestmentsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →